Conatus Pharmaceuticals (NASDAQ:CNAT) has been a lousy pick. Since I last wrote on the company, the shares have dropped more than 40% as investors have fled higher-risk biotech stories. That fellow liver disease specialist Intercept Pharmaceuticals (NASDAQ:ICPT) was down just about as much before an encouraging mid-August trial update is cold comfort, and the company's recent habit of pushing back expected trial data read-outs doesn't help what is already a challenging situation.
Early-stage biotechs are volatile (that goes with the territory) and I'm still bullish on the company's prospects. The company will be announcing data from multiple studies later in 2014 through early/mid-2015 and those announcements could bring momentum back into the shares if the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|